Lilly registers a 2,001-patient Phase 3 of orforglipron in people who are only overweight

Eli Lilly has registered a Phase 3 trial of orforglipron, the oral GLP-1 drug sold as Foundayo, enrolling 2,001 participants who are classified as overweight rather than obese ^[1]. The trial is listed as not yet recruiting ^[1]. Instead of testing the drug in people who already have obesity, the study targets people at risk of developing weight-related health problems or of progressing into class 1 obesity, the mildest category ^[1].

This is a shift in framing. Foundayo was approved for obesity treatment and is already sold in the U.S., with regulatory reviews underway in more than 40 other markets as Lilly works to grow its prescription base ^[2]. Lilly is also planning a regulatory submission for Foundayo in type 2 diabetes this year, and a submission for its next-generation obesity drug retatrutide is expected in early 2027 ^[2]. The new overweight-focused trial adds a third track to that expansion push, testing whether the pill can be used earlier, before someone reaches an obesity diagnosis ^[1].

The registration comes amid a broader wave of clinical activity across the GLP-1 field. In the same monitoring period, a separate Lilly trial of orforglipron for obstructive sleep apnea in people with obesity or overweight moved its completion date four months earlier, to July 2026, and grew its enrollment from 600 to 712 participants after being marked completed ^[1]. Lilly has also registered a Phase 3 pediatric trial of tirzepatide, the molecule in Mounjaro and Zepbound, for children ages 6 to under 12 with obesity, enrolling 150 participants ^[1]. None of the sources provided give a start date, completion date, or specific efficacy targets for the new 2,001-patient overweight trial itself ^[1].

Why it matters for patients

Current GLP-1 labels generally require either a diagnosis of obesity or overweight combined with a weight-related health condition. A trial built around people who are only overweight, with no complication yet, tests whether the drug could someday be used to prevent progression to obesity rather than treat it after the fact ^[1]. If the trial succeeds and Lilly seeks a label expansion, it could widen the population considered eligible for the drug well beyond current criteria.

That kind of expansion would also intensify disputes with insurers and government payers over who gets coverage. The obesity drug market has already been described as one of the fastest-growing in pharmaceuticals, with sales reaching $66 billion last year and forecasts ranging from $105 billion to $200 billion by 2027, according to analysts cited by BioSpace ^[2]. A temporary Medicare GLP-1 Bridge program launched in July was estimated to expand coverage by about 35%, reaching roughly 20 million potential patients ^[2]. Broadening eligibility criteria through a trial like this one could add pressure to that access debate, though none of the sources say how payers might respond to a prevention-focused indication specifically.

For an individual reader, what matters most right now is that this is a single newly registered trial that has not yet begun recruiting ^[1]. No results, safety data, or timeline for completion are available in the sources reviewed.

What happens next

The trial's recruiting status has not changed as of the most recent snapshot, and no start date has been reported ^[1]. Separately, Lilly's oral GLP-1 obstructive sleep apnea study, which also involves people with obesity or overweight, was marked completed with a results date of July 21, 2026 ^[1]. Lilly is expected to submit Foundayo for a type 2 diabetes indication sometime this year, and a retatrutide submission for obesity and overweight is expected in early 2027 ^[2]. Whether or when the new overweight-only Phase 3 trial begins enrolling, and how it might affect future labeling, is not yet known from the available sources.